- Home
- SLGN vs ARWR Comparison
SLGN vs ARWR Comparison
Compare SLGN & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGN
- ARWR
- Stock Information
- Founded
- SLGN 1987
- ARWR 2003
- Country
- SLGN United States
- ARWR United States
- Employees
- SLGN N/A
- ARWR N/A
- Industry
- SLGN Containers/Packaging
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- SLGN Industrials
- ARWR Health Care
- Exchange
- SLGN Nasdaq
- ARWR Nasdaq
- Market Cap
- SLGN 4.5B
- ARWR 4.9B
- IPO Year
- SLGN 1997
- ARWR 1993
- Fundamental
- Price
- SLGN $43.17
- ARWR $36.84
- Analyst Decision
- SLGN Strong Buy
- ARWR Strong Buy
- Analyst Count
- SLGN 9
- ARWR 8
- Target Price
- SLGN $60.11
- ARWR $47.75
- AVG Volume (30 Days)
- SLGN 1.1M
- ARWR 2.0M
- Earning Date
- SLGN 10-29-2025
- ARWR 11-25-2025
- Dividend Yield
- SLGN 1.85%
- ARWR N/A
- EPS Growth
- SLGN N/A
- ARWR N/A
- EPS
- SLGN 2.81
- ARWR N/A
- Revenue
- SLGN $6,162,113,000.00
- ARWR $572,976,000.00
- Revenue This Year
- SLGN $11.86
- ARWR $21,421.26
- Revenue Next Year
- SLGN $2.75
- ARWR N/A
- P/E Ratio
- SLGN $15.36
- ARWR N/A
- Revenue Growth
- SLGN 5.49
- ARWR 2816.20
- 52 Week Low
- SLGN $41.30
- ARWR $9.57
- 52 Week High
- SLGN $58.14
- ARWR $40.29
- Technical
- Relative Strength Index (RSI)
- SLGN 48.06
- ARWR 62.26
- Support Level
- SLGN $41.83
- ARWR $34.61
- Resistance Level
- SLGN $43.68
- ARWR $40.29
- Average True Range (ATR)
- SLGN 0.86
- ARWR 1.67
- MACD
- SLGN 0.23
- ARWR -0.21
- Stochastic Oscillator
- SLGN 67.42
- ARWR 48.82
About SLGN Silgan Holdings Inc.
Silgan Holdings manufactures about half of the metal food containers in North America. Its major customers include Campbell Soup, Nestle, and Del Monte. Silgan's other business segments include plastic dispensers and containers for personal and healthcare products and a closures business that manufactures metal and plastic lids and caps.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.